[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100383858":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":40,"centralContacts":44,"locations":49,"responsibleParty":73,"collaborators":39,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":39,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":39,"enrollmentInfo":84,"targetDuration":39,"studyType":87,"phases":88,"briefSummary":91,"conditions":92,"keywords":39,"overallStatus":52,"whyStopped":39,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Bionic Sight LLC","INDUSTRY",[8,14,18,22,26,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","BSO1 Cohort 1 dose",[13],"Drug: BS01",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","BS01 Cohort 2 dose",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3","BS01 Cohort 3 dose",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohort 4","BS01 Cohort4 dose",[13],{"label":27,"type":10,"description":24,"interventionNames":28},"Cohort 5",[13],{"label":30,"type":10,"description":31,"interventionNames":32},"Cohort 6","Treat opposite eye",[13],[34],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DRUG","BS01","Non-replicating, rep\u002Fcap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)",[9,15,19,23,27,30],null,[41],{"name":42,"affiliation":5,"role":43},"Sheila Nirenberg, PhD","STUDY_DIRECTOR",[45],{"name":46,"role":47,"phone":39,"phoneExt":39,"email":48},"Minako Koga","CONTACT","mkoga@kmphc.com",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"New Jersey Retina","RECRUITING","Teaneck","New Jersey","07666","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-74.01597,40.8976,{"lat":62,"lon":61},[65,70],{"name":66,"role":47,"phone":67,"phoneExt":68,"email":69},"Lauryn Onkendi","(201)837-7300","opt. 4","lonkendi@njretina.com",{"name":71,"role":72,"phone":39,"phoneExt":39,"email":39},"Paul Hahn, MD","PRINCIPAL_INVESTIGATOR",{"type":74,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100383858","phase-1-bs01-in-patients-with-retinitis-pigmentosa-100383858",false,"NCT04278131","BS01 in Patients With Retinitis Pigmentosa","Phase 1\u002F2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP in Patients With Retinitis Pigmentosa","Inclusion Criteria:\n\n* Confirmed diagnosis of retinitis pigmentosa\n* At least one eye with vision no better than 20\u002F160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 30°.\n\nExclusion Criteria:\n\n* Prior receipt of any AAV gene therapy product\n* Large amplitude nystagmus","ALL","18 Years",{"count":85,"type":86},20,"ESTIMATED","INTERVENTIONAL",[89,90],"PHASE1","PHASE2","A Phase 1\u002F2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa",[93],"Retinitis Pigmentosa","2026-01-21",{"date":96,"type":97},"2026-01-23","ACTUAL",{"date":99,"type":97},"2020-02-06",{"date":101,"type":86},"2029-12-30",{"name":5,"class":6},1]